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Results: A multivariate model that was optimized with 
stepwise backward regression indicated that tree 
parameters: clinical N stage 2 or 3 (RR=1.85), high ESR 
(RR=1.74) and high platelet/hemoglobin ratio (RR=1.67) 
independently and negatively influenced overall survival. The 
actuarial 3-year overall survival was 27%. Patients with no 
risk features had 3-year OS of 60%, those with 1 risk factor 
had 3-year OS of 25%, while those with 2-3 risk factors had 3-
year OS of 10% (p<0.001, RR=2.08). OP correlated with ESR 
(correlation coefficient 0.42, p<0.05). The model of 3 year 
overall survival yielded an AUC of 70% (specificity 69,6%, 
sensitivity 62,2%). 
Conclusions: Platelet/hemoglobin ratio and erythrocyte 
sedimentation rate are readily available strong 
prognosticators of overall survival in curative radio-
chemotherapy for locally advanced non-small cell lung 
cancer. The outcome support the studies that suggest that 
inflammation-related parameters (such as ESR) should be 
routinely considered in determination of the prognosis of 
NSCLC.  
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Purpose/Objective: Recent trials of stereotactic 
radiotherapy (SBRT) for lung cancer exclude central lesions, 
tumors considered within or affecting the area of the 
proximal bronchial tree defined as 'a volume of 2 cm in all 
directions around proximal bronchial tree'. Several series for 
central tumors have been published with various doses and 
fractionation. These series often proposed a scheme with a 
Biological Effective Dose (BED) less than 100 Gy to minimize 
the risk of toxicity. We investigated our original institutional 
experience using SBRT for central lung tumor with a scheme 
delivering 75 Gy in 5 fractions of 15 Gy leading to a BED of 
187.5 Gy.  
Materials and Methods: Our institutional SBRT database 
retrospectively collected demographic and treatment-related 
data from all patients treated at our Center. We analyzed all 
patients with central lung tumors treated with SBRT between 
September 2008 and September 2012. Local control (LC) and 
overall survival (OS) were calculated using Kaplan- Meier 
estimates. Toxicity was graded using the Radiation Therapy 
Oncology Group Common Toxicity Criteria. Tumor response 
was scored using Response Evaluation Criteria in Solid Tumors 
v1.1. Predictors for toxicity, LC, and OS were analyzed using 
Cox proportional hazard regression models. 
Results: A total of 43 central lesions in 41 patients (23 with 
primary, 12 with metastatic tumors, 6 no biopsy proven) 
were treated. Median age was 71 years (range: 51-88) and 
median follow up was 24.4 months (1-67). Seventeen patients 
had prior surgery: 10 lobectomies, 3 pneumonectomies, 4 
wedge resections. Radiation was delivered in 5 equal 
fractions of 12 to 15 Gy each to a median prescription isodose 
line of 78.9% (range, 68-80%). Thirty-four tumors (79%) were 
treated with the original regime (75 Gy= 5 X 15 Gy). In order 
to respect the dose constraints of organs at risk we have 
changed the dose per fraction for 9 tumors (21%) (n= 4: 70 
Gy/5 Fr; n=5: 60 Gy/5 Fr). Overall, there were 4 local 
failures resulting in 1-year LC rate and 3-years local LC rate 
of 82.2% and 78.5% respectively. Grade 3 toxicities were 
dyspnea (n = 2), pneumonia (n = 3), pleural effusion (n = 1) 
and parietal pain (n = 1). One patient previously treated by 
pneumonectomy died of dyspnea grade V 12.9 months after 
treatment. The actuarial 1-year and 3-year overall survival 
was respectively 89.4% and 52.7%. 
Conclusions: SBRT for central lung tumors offers high rates 
of local control and acceptable toxicity rates comparable to 
published data for peripheral tumors. 
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Purpose/Objective: To describe a new technique of External 
Radiotherapy Hypofractionated with immobilised patient and 
with the Lung arrested, which we have set into motion in our 
centre and which we have called: 'Arrested Lung Ablative 
Radiotherapy' (ALART). The second objective was to 
investigate the possible parameters of movement in the 
treatment. 
Materials and Methods: We use this technique in four 
patients, treated with RT-54Gy (3 fractions); IMRT: 34 and 
27Gy two lesions (1 fraction), RT-32Gy (1 fraction) and RT-
30Gy (1 fraction). To carry out the technique, general 
anaesthesia is applied with mechanical ventilation until we 
arrested the lung, to achieve that we use a portable extra-
corporeal membrane oxygenation (ECMO) device 
(Cardiohelp™-Maquet©) with a Normo-hypothermia module by 
femoral (arterio-venous) cannulation. For the transport and 
immobilization of the patient we used the Image Provider® 
(SIHO©) transfer trolley with vacuum mattress immobilizer 
and an abdominal compressor frame with the ECMO device, 
keeping the lung arrested and immobilized from the Plan-CT 
to the CT-post-Treatment. The calculation was done with a 
TPS XiO (CMS-Elekta). For the positioning of the patient we 
used a stereotaxic system Exactrac® (Brainlab©) and 
ConeBeam (Elekta). The LINAC was a Primus (Siemens) and 
Synergy (Elekta) using the portal image system in movie 
mode and the Exactrac® to monitorized the movement of the 
patient in the Siemens LINAC and the ConeBeam imaging for 
the Synergy LINAC. We fused through rigid fusion the pre-CT 
and the Post-CT at the level of the tumour and at a global 
level. In each of the fusions we transferred PTVs & GTVs and 
we measured the distances between the center of the 
volumes. 
